Prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India.

Viral hepatitis caused by the hepatitis C virus (HCV) and hepatitis B virus (HBV) represents a major public health problem in India. These viruses share common modes of transmission, such as parenteral routes. We aimed to assess the exposure of a tribal population to these viruses in south India. The present study was carried out on serum samples from 890 individuals (526 males and 324 females) belonging to the Lambada tribe residing in the state of Andhra Pradesh, south India. Anti-HCV antibody and hepatitis B surface antigen (HBsAg) status in the sera were analyzed using commercially available enzyme immunoassays (Abbott Labs, Chicago, IL). HCV-RNA and HBV-DNA in the sera was tested by reverse transcriptase polymerase chain reaction (RT-PCR) and PCR, respectively. The infecting genotype of HCV was determined using type-specific primers corresponding to the NS5 region of the virus. Out of the 890 samples, 18 (2.02%; male 11/526; female 7/364) were positive for HCV-RNA by RT-PCR and, 17 of them were positive for anti-HCV antibody. Genotyping of HCV isolates from the 18 individuals positive for HCV-RNA revealed that 66.67% (12/18) were infected with type 1 of HCV and its variants; while in the remaining (6/18), the infecting genotype was found to be type 3 and its variants. A total of 46 samples (5.16%; males 28/526; female 18/364) were positive for HBsAg; while 11 were positive only for HBV-DNA, 9 were positive for both hepatitis B e antigen (HBeAg) and HBV-DNA. Cultural practices such as tattooing, traditional medicine (e.g. blood-letting), rituals (e.g. scarification), body-piercing etc are the potential sources of spread of infection in this tribe. None of the samples analyzed revealed co-infection with the 2 viruses.

Hepatitis C virus (HCV)--a review molecular biology of the virus, immunodiagnostics, genomic heterogeneity and the role of virus in hepatocellular carcinoma.

Hepatitis C virus (HCV), an RNA and a hepatotropic virus, is the leading cause of viral hepatitis worldwide. Infection with this virus causes a repertoire of liver diseases that include acute hepatitis, chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC), in addition to a number of extra-hepatic manifestations such as lichen planus, oral cancer, etc. At present, patients infected with this virus are treated with interferon either alone or in combination with ribavirin, a guanosine-like nucleoside analog. However, response to this treatment has been rather disappointing. For about a decade, lack of an alternative animal model other than chimpanzee, and an efficient cell culture system that could support long-term replication of the virus, hampered research on HCV. Despite this, a significant amount of information with regard to the molecular biology of the virus is available using bacterial cloning-expression systems, and based on computer predictions and analysis. Recent discovery of a cellular receptor to which the virus binds, identification of efficient cell culture/cell-free systems, HCV replicons and the development of a chimeric mouse model, provide a platform to verify the existing knowledge about this virus in the coming years. Additionally these developments aid the researchers in identifying novel therapeutic agents, apart from allowing us to reassess the efficiency of the currently available therapeutics. Presented in this article are a review of existing information with regard to the molecular biology of the virus, immunodiagnostic assays, genomic heterogeneity and the role of the virus in hepatocellular carcinoma. Likely therapeutic strategies other than those currently available are also introduced.